Put companies on watchlist
Organon & Co.
ISIN: US68622V1061
WKN: A3CPKP
More AI Integrations
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

Organon & Co. · ISIN: US68622V1061 · Business Wire (ID: 20250603434719)
03 June 2025 06:13PM

Law Offices of Frank R. Cruz Encourages Organon & Co. (OGN) Investors to Inquire About Securities Fraud Class Action


Law Offices of Frank R. Cruz Encourages Organon & Co. (OGN) Investors to Inquire About Securities Fraud Class Action

The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of investors who purchased Organon & Co. (“Organon” or the “Company”) (NYSE: OGN) securities between October 31, 2024 to April 30, 2025, inclusive (the “Class Period”). Organon investors have until July 22, 2025 to file a lead plaintiff motion.

IF YOU SUFFERED A LOSS ON YOUR ORGANON & CO. (OGN) INVESTMENTS, CLICK HERE TO SUBMIT A CLAIM TO POTENTIALLY RECOVER YOUR LOSSES IN THE ONGOING SECURITIES FRAUD LAWSUIT.

You can also contact the Law Offices of Frank R. Cruz to discuss your legal rights by email at info@frankcruzlaw.com, by telephone at (310) 914-5007, or visit our website at www.frankcruzlaw.com.

What Happened?

On May 1, 2025, Organon released its first quarter 2025 financial results, announcing that management had reset the Company’s dividend payout, from $0.28 to $0.02 and would “redirect those funds to debt reduction.”

On this news, Organon’s stock price fell $3.48, or 26.9%, to close at $9.45 per share on May 1, 2025, thereby injuring investors.

What Is The Lawsuit About?

The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) Organon’s optimistic reports of the dividend payout as the Company’s “number one priority,” were offset by Organon’s newly implemented debt reduction strategy, thus, leading to a drastic decrease – over 70% – of the quarterly dividend; (2) Organon planned to prioritize debt reduction following the Company’s acquisition of Dermavant; and (3) as a result, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.

Contact Us To Participate or Learn More:

If you purchased Organon securities, wish to learn more about this action, or have any questions concerning this announcement or your rights or interests with respect to these matters, please click HERE or contact us at:

Law Offices of Frank R. Cruz
2121 Avenue of the Stars, Suite 800
Telephone: 310-914-5007
Email: info@frankcruzlaw.com
Visit our website at: www.frankcruzlaw.com

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contact

Law Offices of Frank R. Cruz
2121 Avenue of the Stars, Suite 800
Telephone: 310-914-5007
Email: info@frankcruzlaw.com
Visit our website at: www.frankcruzlaw.com

Visual performance / price development - Organon & Co.
Smart analysis and research tools can be found here.
MIC: XNYS
This publication was provided by our content partner Business Wire
BusinessWire
via BusinessWire - Newsfeed
BusinessWire ©2025
BusinessWire
Contact:
101 California Street, 20th Floor San Francisco, CA, 94111 United States
+1.415.986.4422